Cargando…

Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study

PURPOSE: Individuals with polycystic ovary syndrome (PCOS) are at increased risk of depression and anxiety symptoms and impairment in aspects of cognitive function. However, there is little evidence regarding effects of standard treatment for PCOS on these features of the syndrome. The aim of this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sukhapure, Mayouri, Eggleston, Kate, Fenton, Anna, Frampton, Christopher, Porter, Richard J, Douglas, Katie M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675344/
https://www.ncbi.nlm.nih.gov/pubmed/36411778
http://dx.doi.org/10.2147/NDT.S385014
_version_ 1784833353075130368
author Sukhapure, Mayouri
Eggleston, Kate
Fenton, Anna
Frampton, Christopher
Porter, Richard J
Douglas, Katie M
author_facet Sukhapure, Mayouri
Eggleston, Kate
Fenton, Anna
Frampton, Christopher
Porter, Richard J
Douglas, Katie M
author_sort Sukhapure, Mayouri
collection PubMed
description PURPOSE: Individuals with polycystic ovary syndrome (PCOS) are at increased risk of depression and anxiety symptoms and impairment in aspects of cognitive function. However, there is little evidence regarding effects of standard treatment for PCOS on these features of the syndrome. The aim of this study was to examine the effect of 12 weeks of naturalistic treatment of PCOS, with usual medications, on depression symptoms, anxiety symptoms and cognitive function. PATIENTS AND METHODS: Thirty-three participants with PCOS received 12 weeks of individualised treatment based on clinical presentation. Changes in depression and anxiety symptoms were assessed with the self-report Hospital Anxiety and Depression Scale at baseline and 12 weeks, and cognitive function was assessed at the same time-points with a battery of tests spanning cognitive domains of verbal learning and memory, visuospatial learning and memory, psychomotor speed, attention and executive function. Outcomes were compared with a control group of 40 healthy participants. RESULTS: Participants with PCOS (mean age = 29.2 years; mean Body Mass Index = 27.4) were treated with a variety of medications, predominantly spironolactone (n = 22) and oral contraceptives (n = 16). Depression and anxiety symptoms improved significantly over the course of treatment, with moderate effect sizes (Cohen’s d 0.43–0.55, p < 0.05). Effect sizes of the difference in change from that of the control group were moderate but did not reach statistical significance. Women undergoing PCOS treatment demonstrated significant improvements in aspects of cognitive function, but improvement did not differ significantly from controls and effect size changes were similar, suggesting practise effects in both groups. CONCLUSION: Our study provides preliminary evidence that treatment of PCOS may be associated with improvement in psychiatric aspects of the syndrome, particularly depressive symptoms.
format Online
Article
Text
id pubmed-9675344
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96753442022-11-20 Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study Sukhapure, Mayouri Eggleston, Kate Fenton, Anna Frampton, Christopher Porter, Richard J Douglas, Katie M Neuropsychiatr Dis Treat Original Research PURPOSE: Individuals with polycystic ovary syndrome (PCOS) are at increased risk of depression and anxiety symptoms and impairment in aspects of cognitive function. However, there is little evidence regarding effects of standard treatment for PCOS on these features of the syndrome. The aim of this study was to examine the effect of 12 weeks of naturalistic treatment of PCOS, with usual medications, on depression symptoms, anxiety symptoms and cognitive function. PATIENTS AND METHODS: Thirty-three participants with PCOS received 12 weeks of individualised treatment based on clinical presentation. Changes in depression and anxiety symptoms were assessed with the self-report Hospital Anxiety and Depression Scale at baseline and 12 weeks, and cognitive function was assessed at the same time-points with a battery of tests spanning cognitive domains of verbal learning and memory, visuospatial learning and memory, psychomotor speed, attention and executive function. Outcomes were compared with a control group of 40 healthy participants. RESULTS: Participants with PCOS (mean age = 29.2 years; mean Body Mass Index = 27.4) were treated with a variety of medications, predominantly spironolactone (n = 22) and oral contraceptives (n = 16). Depression and anxiety symptoms improved significantly over the course of treatment, with moderate effect sizes (Cohen’s d 0.43–0.55, p < 0.05). Effect sizes of the difference in change from that of the control group were moderate but did not reach statistical significance. Women undergoing PCOS treatment demonstrated significant improvements in aspects of cognitive function, but improvement did not differ significantly from controls and effect size changes were similar, suggesting practise effects in both groups. CONCLUSION: Our study provides preliminary evidence that treatment of PCOS may be associated with improvement in psychiatric aspects of the syndrome, particularly depressive symptoms. Dove 2022-11-15 /pmc/articles/PMC9675344/ /pubmed/36411778 http://dx.doi.org/10.2147/NDT.S385014 Text en © 2022 Sukhapure et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sukhapure, Mayouri
Eggleston, Kate
Fenton, Anna
Frampton, Christopher
Porter, Richard J
Douglas, Katie M
Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study
title Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study
title_full Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study
title_fullStr Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study
title_full_unstemmed Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study
title_short Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study
title_sort changes in mood, anxiety, and cognition with polycystic ovary syndrome treatment: a longitudinal, naturalistic study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675344/
https://www.ncbi.nlm.nih.gov/pubmed/36411778
http://dx.doi.org/10.2147/NDT.S385014
work_keys_str_mv AT sukhapuremayouri changesinmoodanxietyandcognitionwithpolycysticovarysyndrometreatmentalongitudinalnaturalisticstudy
AT egglestonkate changesinmoodanxietyandcognitionwithpolycysticovarysyndrometreatmentalongitudinalnaturalisticstudy
AT fentonanna changesinmoodanxietyandcognitionwithpolycysticovarysyndrometreatmentalongitudinalnaturalisticstudy
AT framptonchristopher changesinmoodanxietyandcognitionwithpolycysticovarysyndrometreatmentalongitudinalnaturalisticstudy
AT porterrichardj changesinmoodanxietyandcognitionwithpolycysticovarysyndrometreatmentalongitudinalnaturalisticstudy
AT douglaskatiem changesinmoodanxietyandcognitionwithpolycysticovarysyndrometreatmentalongitudinalnaturalisticstudy